Vertex Pharmaceuticals develops and commercializes therapies for cystic fibrosis (CF) and other diseases. Products include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The pipeline includes VX-522 for CF, VX-548 for pain, Exa-cel for sickle cell disease and beta thalassemia, and others. Inaxaplin treats APOL1-mediated glomerulosclerosis and hypertension. Vertex also develops treatments for Type 1 Diabetes, cancer, and Duchenne muscular dystrophy with various partners. The company sells products to specialty pharmacies and distributors in the US and abroad. Founded in 1989, Vertex is headquartered in Boston, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 27.5 |
| EV/EBITDA | 20.1 |
| Price/Free Cash Flow' | 34.0 |
| ROIC | 17.5% |
| Net Debt/EBITDA | -0.6 |